The Communication of Genetic Risk to Adolescent Daughters of Women With Breast Cancer

Breast Cancer Clinical Trial

Official title:

The Communication of Genetic Risk to Adolescent Daughters of Women With Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00588705
• Other study ID #: 07-063
• Status: Completed
• Phase: N/A
• First received: December 24, 2007
• Last updated: January 27, 2017
• Start date: December 2007
• Est. completion date: January 2017

Study information

• Verified date: January 2017
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to first understand how MSKCC Clinical Genetics Service doctors talk to women with breast cancer about any genetic risks they might carry, and if they help women to think about what they might say, in turn, to their relatives, especially their daughters.

A second part of the study asks women for their opinions about when and how their daughters should be told about any genetic risks.

All of this will help us develop teaching methods to help our doctors improve the way they talk about genetic risk when women with breast cancer have adolescent daughters.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 27
• Est. completion date: January 2017
• Est. primary completion date: January 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 12 Years to 20 Years

Eligibility

Inclusion Criteria:

• Women seen in the MSK CGS Service who have a diagnosis of breast cancer or

• a family history of breast cancer and

• have biological daughter(s) in the age range 12-20 years will be eligible to participate in Phase I & II.

• Women who were consented to Phase I will automatically be eligible for Phase II.

Exclusion Criteria:

• Women seen in the MSK CGS Service will be ineligible if they have no diagnosis of breast cancer and no family history of breast cancer,

• do not have a biological daughter,

• or have a biological daughter fewer than 12 or greater than 20 years(unless they were consented to Phase 1).

• Women will be ineligible if they are not English speaking,

• have intellectual or cognitive impairment,

• or active mental illness rendering them incapable of giving informed consent, such as might occur with active psychosis.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Counseling

Intervention

Behavioral:
• focus group & questionaire
The focus group will last about 90 minutes. However, your involvement in this study will last from the time you join until you read over the summary of what happened during the focus group and return your comments. This should be approximately 2 months. Patient will complete a questionnaire and we estimate total time for completion to be approximately 7 minutes.

Locations

Country	Name	City	State
United States	Memorial Sloan-Kettering Cancer Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	Monash University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Is a demonstration of the effectiveness of the module in changing the behavior of clinicians after taking part in the communication skills module.		conclusion of study
Secondary	To examine the views of women about the provision of genetic risk information to their daughters.		conclusion of study

External Links

•   Memorial Sloan-Kettering Cancer Center